AVTX missed EPS expectations by 29.44%
Nov 07, 2025, 11:36 PM
0.00%
What does AVTX do
Avalo Therapeutics, a clinical-stage biotechnology company headquartered in Rockville, Maryland, focuses on immune dysregulation therapies, with key assets including AVTX-009, quisovalimab, and AVTX-008. The company went public on November 13, 2015, and employs 19 people.
Avalo Therapeutics (AVTX) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Avalo Therapeutics's actual EPS was -$2.19, missing the estimate of -$1.69 per share, resulting in a -29.44% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.